NANOBIOTIX (EPA:NANO) | WebDisclosure

Basculer en Français

11221	Companies
248818	Keywords
176608	Articles
134647	Press releases

Home
Companies
NANOBIOTIX

PRESS RELEASE

published on 10/01/2025 at 22:15, 1 year ago

NANOBIOTIX annonce les premières données de Phase 1 évaluant JNJ-1900 (NBTXR3) chez des patients atteints de cancer de l’œsophage
Nanobiotix annonce les premières données de phase 1 évaluant JNJ-1900 (NBTXR3) chez des patients atteints de cancer de l’œsophage. Taux de contrôle de la maladie de 85% et taux de réponse objective de 69%

NANOBIOTIX Phase 1 JNJ-1900 ASTRO Cancer De L’œsophage
PRESS RELEASE

published on 09/30/2025 at 22:27, 1 year ago

RAPPORT FINANCIER SEMESTRIEL
BRIEF

published on 09/30/2025 at 22:20, 1 year ago

Nanobiotix : Bilan financier et avancées cliniques au 1er semestre 2025

Résultats Financiers Biotechnologie NANOBIOTIX Johnson & Johnson JNJ-1900
BRIEF

published on 09/30/2025 at 22:20, 1 year ago

Nanobiotix: Financial results and clinical progress in the first half of 2025

Financial Results Biotechnology NANOBIOTIX Johnson & Johnson JNJ-1900
PRESS RELEASE

published on 09/30/2025 at 22:15, 1 year ago

NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers pour le premier semestre 2025
Nanobiotix fait le point sur ses activités et publie ses résultats financiers pour le premier semestre 2025, marqué par le développement clinique de JNJ-1900 et une gestion financière rigoureuse

Résultats Financiers Développement Clinique Gestion Financière NANOBIOTIX JNJ-1900
PRESS RELEASE

published on 09/30/2025 at 22:15, 1 year ago

NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
Nanobiotix provides business update & reports 2025 half year financial results. Highlights clinical development program & financial performance

Financial Results Financial Performance Business Update Clinical Development NANOBIOTIX
BRIEF

published on 09/30/2025 at 00:35, 1 year ago

NANOBIOTIX Reports Promising Phase 1 Results for JNJ-1900 (NBTXR3) in R/M-HNSCC

Phase 1 Trial NANOBIOTIX Clinical Study Results R/M-HNSCC JNJ-1900 (NBTXR3)
BRIEF

published on 09/30/2025 at 00:35, 1 year ago

NANOBIOTIX annonce des résultats prometteurs de phase 1 pour JNJ-1900 (NBTXR3) dans le traitement du carcinome épidermoïde œsophagien (HNSCC) métastatique (R/M)

NANOBIOTIX Essai De Phase 1 Résultats Des Études Cliniques R/M-HNSCC JNJ-1900 (NBTXR3)
PRESS RELEASE

published on 09/30/2025 at 00:30, 1 year ago

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
Nanobiotix announces updated phase 1 results supporting JNJ-1900 plus anti-PD-1 as a new option in R/M-HNSCC. Promising local and systemic responses presented at ASTRO 2025

NANOBIOTIX Anti-PD-1 JNJ-1900 R/M-HNSCC ASTRO 2025
BRIEF

published on 09/17/2025 at 22:20, 1 year 1 month ago

Nouveaux résultats positifs pour NANOBIOTIX dans l'étude de Phase 1 sur le mélanome

Efficacité NANOBIOTIX Phase 1 Mélanome JNJ-1900

Accesswire

Published on 10/23/2026 at 13:23, 53 minutes ago

Slam Mobilizes Drill Team to Moose Lake, Intersecting Broad Zones of Brecciated and Altered Rock With Visible Stibnite Along the Moose Lake Fault Zone
Published on 10/23/2026 at 13:00, 1 hour 16 minutes ago

First Canadian Graphite Inc. Announces Flow-Through Financing
Published on 10/23/2026 at 13:00, 1 hour 16 minutes ago

First Canadian Graphite Inc. annonce un financement accréditif
Published on 10/23/2026 at 02:20, 11 hours 56 minutes ago

Apex Announces Nasdaq Listing and Pricing of US$1.86 Million Offering
Published on 10/22/2026 at 23:30, 14 hours 46 minutes ago

Cypher Announces Subscription Receipt Offering

View all ACCESSWIRE

EQS Group

Published on 10/23/2026 at 14:00, 16 minutes ago

Alzchem again ranked among the top 5% of companies rated worldwide by EcoVadis
Published on 10/23/2026 at 13:25, 51 minutes ago

India's Spiritual Leadership Takes Center Stage Globally: *H.H. Shree Shivkrupanand Swami, promoter of global spritual platform 'Gurutattva' and 'Himalayan Samarpan Meditation', appointed Vice Chair of 'World Meditation Day Governance Committee'
Published on 10/23/2026 at 12:54, 1 hour 22 minutes ago

EQS-Adhoc: Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München: Munich Re reports quarterly net profit of €1.7bn and raises full-year guidance
Published on 10/23/2026 at 12:46, 1 hour 30 minutes ago

Cairn Homes Plc: Holding(s) in Company
Published on 10/23/2026 at 12:38, 1 hour 38 minutes ago

Cairn Homes Plc: Holding(s) in Company

Les Echos

Published on 10/23/2026 at 07:00, 7 hours 16 minutes ago

Safran reports third quarter 2026 revenue
Published on 10/23/2026 at 07:00, 7 hours 16 minutes ago

Safran publie son chiffre d’affaires du 3e trimestre 2026
Published on 10/22/2026 at 18:00, 20 hours 16 minutes ago

THERMADOR GROUPE : Completion of the share buy-back programme launched in August
Published on 10/22/2026 at 18:00, 20 hours 16 minutes ago

THERMADOR GROUPE : Fin du programme de rachat d’actions débuté en août
Published on 10/22/2026 at 18:00, 20 hours 16 minutes ago

bioMérieux receives Dual 510(k) Clearance and CLIA Waiver from the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel to Advance Women’s Health with Rapid Molecular Diagnostics

View all LES ECHOS COMFI WIRE